title: Modern oncological approaches to gastric adenocarcinoma.
abstract: Gastric cancer (GC) is a major health burden throughout the world, especially in certain endemic regions. GC is commonly diagnosed at an advanced stage because of the lack of early detection strategies and is usually associated with a dismal outcome. For patients with localized GC (LGC), surgery is the best cure: cure rates are highly associated with the surgical pathology stage. Adjunctive therapies improve the cure rates by about an additional 10%. Therefore, a multimodality approach is highly recommended for all patients with LGC. This article highlights some of the therapeutic advances made against GC and features important ongoing trials.
authors: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors: Roopma
authors: R
authors: Wadhwa
authors: Takashi
authors: T
authors: Taketa
authors: Kazuki
authors: K
authors: Sudo
authors: Mariela A
authors: MA
authors: Blum
authors: Jaffer A
authors: JA
authors: Ajani
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D059186:Chemoradiotherapy, Adjuvant; D017024:Chemotherapy, Adjuvant; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005743:Gastrectomy; D006801:Humans; D058990:Molecular Targeted Therapy; D020360:Neoadjuvant Therapy; D019859:Proto-Oncogene Proteins c-met / Q000378:metabolism; D015398:Signal Transduction / Q000235:genetics; D013274:Stomach Neoplasms / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D000068878:Trastuzumab; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D066246:ErbB Receptors; D019859:Proto-Oncogene Proteins c-met; D000068878:Trastuzumab